The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
Kristina Vermeersch,1 Maria Gabrovska,2 Griet Deslypere,3 Ingel K Demedts,4 Hans Slabbynck,5 Joseph Aumann,3 Vincent Ninane,2 Geert M Verleden,1 Thierry Troosters,1,6 Kris Bogaerts,7,8 Guy G Brusselle,9 Wim Janssens1 On behalf of the BACE Trial Investigators 1KU Leuven, Laboratory of Resp...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-03-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/the-belgian-trial-with-azithromycin-for-acute-copd-exacerbations-requi-peer-reviewed-article-COPD |
id |
doaj-76ff9a7ed6b9436f9a80161b3552ab1f |
---|---|
record_format |
Article |
spelling |
doaj-76ff9a7ed6b9436f9a80161b3552ab1f2020-11-24T22:39:57ZengDove Medical PressInternational Journal of COPD1178-20052016-03-012016Issue 168769626229The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trialVermeersch KGabrovska MDeslypere GDemedts IKSlabbynck HAumann JNinane VVerleden GMTroosters TBogaerts KBrusselle GGJanssens WKristina Vermeersch,1 Maria Gabrovska,2 Griet Deslypere,3 Ingel K Demedts,4 Hans Slabbynck,5 Joseph Aumann,3 Vincent Ninane,2 Geert M Verleden,1 Thierry Troosters,1,6 Kris Bogaerts,7,8 Guy G Brusselle,9 Wim Janssens1 On behalf of the BACE Trial Investigators 1KU Leuven, Laboratory of Respiratory Diseases, Department of Clinical and Experimental Medicine, Faculty of Medicine, Leuven, Belgium; 2Department of Pneumology, Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium; 3Department of Pneumology, Jessa Ziekenhuis, Hasselt, Belgium; 4Department of Respiratory Medicine, AZ Delta Roeselare-Menen, Roeselare, Belgium; 5Department of Respiratory Medicine, ZNA Middelheim, Antwerpen, Belgium; 6KU Leuven, Department of Rehabilitation Sciences, Faculty of Kinesiology and Rehabilitation Sciences, Leuven, Belgium; 7KU Leuven, Department of Public Health and Primary Care, I-BioStat, Leuven, Belgium; 8Hasselt University, Hasselt, Belgium; 9Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium Background: Long-term use of macrolide antibiotics is effective to prevent exacerbations in chronic obstructive pulmonary disease (COPD). As risks and side effects of long-term intervention outweigh the benefits in the general COPD population, the optimal dose, duration of treatment, and target population are yet to be defined. Hospitalization for an acute exacerbation (AE) of COPD may offer a targeted risk group and an obvious risk period for studying macrolide interventions.Methods/design: Patients with COPD, hospitalized for an AE, who have a smoking history of ≥10 pack-years and had ≥1 exacerbation in the previous year will be enrolled in a multicenter, randomized, double-blind, placebo-controlled trial (NCT02135354). On top of a standardized treatment of systemic corticosteroids and antibiotics, subjects will be randomized to receive either azithromycin or placebo during 3 months, at an uploading dose of 500 mg once a day for 3 days, followed by a maintenance dose of 250 mg once every 2 days. The primary endpoint is the time-to-treatment failure during the treatment phase (ie, from the moment of randomization until the end of intervention). Treatment failure is a novel composite endpoint defined as either death, the admission to intensive care or the requirement of additional systemic steroids or new antibiotics for respiratory reasons, or the diagnosis of a new AE after discharge.Discussion: We investigate whether azithromycin initiated at the onset of a severe exacerbation, with a limited duration and at a low dose, might be effective and safe in the highest risk period during and immediately after the acute event. If proven effective and safe, this targeted approach may improve the treatment of severe AEs and redirect the preventive use of azithromycin in COPD to a temporary intervention in the subgroup with the highest unmet needs. Keywords: COPD, acute exacerbation, macrolide antibiotics, azithromycin, physical activity, RCThttps://www.dovepress.com/the-belgian-trial-with-azithromycin-for-acute-copd-exacerbations-requi-peer-reviewed-article-COPDCOPDAcute exacerbationMacrolide antibioticsAzithromycinPhysical activity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vermeersch K Gabrovska M Deslypere G Demedts IK Slabbynck H Aumann J Ninane V Verleden GM Troosters T Bogaerts K Brusselle GG Janssens W |
spellingShingle |
Vermeersch K Gabrovska M Deslypere G Demedts IK Slabbynck H Aumann J Ninane V Verleden GM Troosters T Bogaerts K Brusselle GG Janssens W The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial International Journal of COPD COPD Acute exacerbation Macrolide antibiotics Azithromycin Physical activity |
author_facet |
Vermeersch K Gabrovska M Deslypere G Demedts IK Slabbynck H Aumann J Ninane V Verleden GM Troosters T Bogaerts K Brusselle GG Janssens W |
author_sort |
Vermeersch K |
title |
The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
title_short |
The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
title_full |
The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
title_fullStr |
The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
title_full_unstemmed |
The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
title_sort |
belgian trial with azithromycin for acute copd exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
publisher |
Dove Medical Press |
series |
International Journal of COPD |
issn |
1178-2005 |
publishDate |
2016-03-01 |
description |
Kristina Vermeersch,1 Maria Gabrovska,2 Griet Deslypere,3 Ingel K Demedts,4 Hans Slabbynck,5 Joseph Aumann,3 Vincent Ninane,2 Geert M Verleden,1 Thierry Troosters,1,6 Kris Bogaerts,7,8 Guy G Brusselle,9 Wim Janssens1 On behalf of the BACE Trial Investigators 1KU Leuven, Laboratory of Respiratory Diseases, Department of Clinical and Experimental Medicine, Faculty of Medicine, Leuven, Belgium; 2Department of Pneumology, Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium; 3Department of Pneumology, Jessa Ziekenhuis, Hasselt, Belgium; 4Department of Respiratory Medicine, AZ Delta Roeselare-Menen, Roeselare, Belgium; 5Department of Respiratory Medicine, ZNA Middelheim, Antwerpen, Belgium; 6KU Leuven, Department of Rehabilitation Sciences, Faculty of Kinesiology and Rehabilitation Sciences, Leuven, Belgium; 7KU Leuven, Department of Public Health and Primary Care, I-BioStat, Leuven, Belgium; 8Hasselt University, Hasselt, Belgium; 9Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium Background: Long-term use of macrolide antibiotics is effective to prevent exacerbations in chronic obstructive pulmonary disease (COPD). As risks and side effects of long-term intervention outweigh the benefits in the general COPD population, the optimal dose, duration of treatment, and target population are yet to be defined. Hospitalization for an acute exacerbation (AE) of COPD may offer a targeted risk group and an obvious risk period for studying macrolide interventions.Methods/design: Patients with COPD, hospitalized for an AE, who have a smoking history of ≥10 pack-years and had ≥1 exacerbation in the previous year will be enrolled in a multicenter, randomized, double-blind, placebo-controlled trial (NCT02135354). On top of a standardized treatment of systemic corticosteroids and antibiotics, subjects will be randomized to receive either azithromycin or placebo during 3 months, at an uploading dose of 500 mg once a day for 3 days, followed by a maintenance dose of 250 mg once every 2 days. The primary endpoint is the time-to-treatment failure during the treatment phase (ie, from the moment of randomization until the end of intervention). Treatment failure is a novel composite endpoint defined as either death, the admission to intensive care or the requirement of additional systemic steroids or new antibiotics for respiratory reasons, or the diagnosis of a new AE after discharge.Discussion: We investigate whether azithromycin initiated at the onset of a severe exacerbation, with a limited duration and at a low dose, might be effective and safe in the highest risk period during and immediately after the acute event. If proven effective and safe, this targeted approach may improve the treatment of severe AEs and redirect the preventive use of azithromycin in COPD to a temporary intervention in the subgroup with the highest unmet needs. Keywords: COPD, acute exacerbation, macrolide antibiotics, azithromycin, physical activity, RCT |
topic |
COPD Acute exacerbation Macrolide antibiotics Azithromycin Physical activity |
url |
https://www.dovepress.com/the-belgian-trial-with-azithromycin-for-acute-copd-exacerbations-requi-peer-reviewed-article-COPD |
work_keys_str_mv |
AT vermeerschk thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT gabrovskam thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT deslypereg thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT demedtsik thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT slabbynckh thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT aumannj thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT ninanev thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT verledengm thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT troosterst thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT bogaertsk thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT brussellegg thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT janssensw thebelgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT vermeerschk belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT gabrovskam belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT deslypereg belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT demedtsik belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT slabbynckh belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT aumannj belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT ninanev belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT verledengm belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT troosterst belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT bogaertsk belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT brussellegg belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT janssensw belgiantrialwithazithromycinforacutecopdexacerbationsrequiringhospitalizationaninvestigatorinitiatedstudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial |
_version_ |
1725706815295979520 |